title: [Indications for calcium channel antagonist therapy according to the latest large clinical trials].
authors.affiliation: Katedra i Klinika Nadciśnienia Tetniczego, Chorób Naczyń i Chorób Wewnetrznych AM im. Karola Marcinkowskiego w Poznaniu.
authors.forename: Teresa
authors.initials: T
authors.lastname: Kosicka
authors.forename: Hanna
authors.initials: H
authors.lastname: Kara-Perz
authors.forename: Jerzy
authors.initials: J
authors.lastname: Głuszek
authors.forename: Stanisław
authors.initials: S
authors.lastname: Perz
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000787:Angina Pectoris / Q000188:drug therapy; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000494:pharmacology* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004110:Diltiazem / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D008297:Male; D015201:Meta-Analysis as Topic; D017202:Myocardial Ischemia / Q000188:drug therapy; D009543:Nifedipine / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D014700:Verapamil / Q000627:therapeutic use
chemical_list: D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D014700:Verapamil; D004110:Diltiazem; D009543:Nifedipine